BR112012016853A2 - "pharmaceutical compositions for oral administration of insulin peptides". - Google Patents
"pharmaceutical compositions for oral administration of insulin peptides".Info
- Publication number
- BR112012016853A2 BR112012016853A2 BR112012016853A BR112012016853A BR112012016853A2 BR 112012016853 A2 BR112012016853 A2 BR 112012016853A2 BR 112012016853 A BR112012016853 A BR 112012016853A BR 112012016853 A BR112012016853 A BR 112012016853A BR 112012016853 A2 BR112012016853 A2 BR 112012016853A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- oral administration
- insulin peptides
- insulin
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Abstract
composições farmacêuticas para administração oral de peptídeos de insulina. a invenção é relacionada a composições farmacêuticas apropriadas para administração oral de peptídeos insulina processos de fabricação das mesmas e tratamento com as mesmas.pharmaceutical compositions for oral administration of insulin peptides. The invention relates to pharmaceutical compositions suitable for oral administration of insulin peptides to their manufacturing processes and treatment with them.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10150496 | 2010-01-12 | ||
US29462110P | 2010-01-13 | 2010-01-13 | |
PCT/EP2011/050338 WO2011086093A2 (en) | 2010-01-12 | 2011-01-12 | Pharmaceutical compositions for oral administration of insulin peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012016853A2 true BR112012016853A2 (en) | 2017-10-17 |
Family
ID=42174567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012016853A BR112012016853A2 (en) | 2010-01-12 | 2011-01-12 | "pharmaceutical compositions for oral administration of insulin peptides". |
Country Status (11)
Country | Link |
---|---|
US (2) | US20130058999A1 (en) |
EP (1) | EP2523655A2 (en) |
JP (1) | JP5908847B2 (en) |
KR (1) | KR20120117013A (en) |
CN (1) | CN102753150A (en) |
AU (1) | AU2011206629B2 (en) |
BR (1) | BR112012016853A2 (en) |
CA (1) | CA2786953A1 (en) |
MX (1) | MX2012007806A (en) |
RU (1) | RU2012133075A (en) |
WO (1) | WO2011086093A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
US20140315797A1 (en) | 2010-10-15 | 2014-10-23 | Peter Madsen | Novel N-Terminally Modified Insulin Derivatives |
JP2015502971A (en) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー/エス | N-terminal modified insulin derivative |
EP2820150A1 (en) * | 2012-03-01 | 2015-01-07 | Novo Nordisk A/S | N-terminally modified oligopeptides and uses thereof |
WO2013153000A2 (en) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Insulin formulations |
WO2015010927A1 (en) * | 2013-07-24 | 2015-01-29 | Novo Nordisk A/S | Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating |
TWI728959B (en) * | 2014-11-04 | 2021-06-01 | 因華生技製藥股份有限公司 | Oral administration of unstable or poorly-absorbed drugs |
LT3265140T (en) * | 2015-03-02 | 2021-09-27 | Medlab Clinical U.S., Inc. | Transmucosal and transdermal delivery systems |
GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
HUE055231T2 (en) | 2016-12-16 | 2021-11-29 | Novo Nordisk As | Insulin containing pharmaceutical compositions |
EP3563833A4 (en) * | 2016-12-28 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | Self-emulsifying drug formulation for improving membrane permeability of compound |
JP2021518342A (en) * | 2018-03-13 | 2021-08-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | Virus-like nanocapsid for oral delivery of insulin |
CN108743523B (en) * | 2018-06-11 | 2021-01-12 | 滕川 | Astragalus polysaccharide preparation and preparation method and application thereof |
US11690963B2 (en) | 2018-08-22 | 2023-07-04 | Qnovia, Inc. | Electronic device for producing an aerosol for inhalation by a person |
US11517685B2 (en) | 2019-01-18 | 2022-12-06 | Qnovia, Inc. | Electronic device for producing an aerosol for inhalation by a person |
KR102327750B1 (en) * | 2018-12-19 | 2021-11-18 | 대화제약 주식회사 | Pharmaceutical composition for oral administration comprising GLP-1 agonist |
EP4044843A4 (en) * | 2019-10-20 | 2023-12-06 | Qnovia, Inc. | Liquids for aerosolizing and inhaling using electronic devices |
JP7103403B2 (en) * | 2020-12-25 | 2022-07-20 | 横浜ゴム株式会社 | Adhesive pretreatment agent for vulcanized rubber |
KR20240026573A (en) * | 2022-08-22 | 2024-02-29 | 부산대학교 산학협력단 | Polysorbate-Succinic anhydride-Carnitine Complex and Compositions for Delivering Physiologically Active Substances or Drugs Comprising the Same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0580778B1 (en) | 1991-04-19 | 1999-08-11 | LDS Technologies, Inc. | Convertible microemulsion formulations |
US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
CN1329502A (en) * | 1998-12-04 | 2002-01-02 | 普罗瓦利斯英国有限公司 | Pharmaceutical compositions containing insulin |
WO2001021154A2 (en) | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
CN1160122C (en) | 2001-04-20 | 2004-08-04 | 清华大学 | Method of preparing oil-phase oral insulin preparation |
AUPR510001A0 (en) | 2001-05-18 | 2001-06-14 | Jupitar Pty Ltd | Formulation and method |
US6951655B2 (en) | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
AU2002362040A1 (en) | 2001-12-03 | 2003-06-17 | Dor Biopharma Inc. | Reverse micelle compositions and uses thereof |
BRPI0413276B8 (en) * | 2003-08-05 | 2021-05-25 | Novo Nordisk As | insulin derivative, zinc complex thereof, and pharmaceutical composition |
WO2005046716A1 (en) * | 2003-11-13 | 2005-05-26 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
JP4874989B2 (en) * | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー/エス | Soluble and stable insulin-containing formulation |
BRPI0608152A2 (en) | 2005-02-09 | 2009-11-10 | Macusight Inc | eye care formulations |
BRPI0520704A2 (en) * | 2005-11-30 | 2009-05-19 | Generex Pharm Inc | orally absorbed pharmaceutical formulation and method of administration |
ES2542146T3 (en) * | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | PEGylated extended insulin. |
KR101699370B1 (en) | 2006-09-22 | 2017-02-14 | 노보 노르디스크 에이/에스 | Protease resistant insulin analogues |
EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
WO2008145730A1 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
EP2178912B1 (en) * | 2007-08-15 | 2015-07-08 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
CN102227213A (en) * | 2008-11-28 | 2011-10-26 | 诺沃—诺迪斯克有限公司 | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
JP2013504610A (en) * | 2009-09-16 | 2013-02-07 | ノヴォ ノルディスク アー/エス | Stable non-aqueous liquid pharmaceutical composition comprising insulin |
-
2011
- 2011-01-12 WO PCT/EP2011/050338 patent/WO2011086093A2/en active Application Filing
- 2011-01-12 JP JP2012548420A patent/JP5908847B2/en not_active Expired - Fee Related
- 2011-01-12 BR BR112012016853A patent/BR112012016853A2/en not_active IP Right Cessation
- 2011-01-12 KR KR1020127019959A patent/KR20120117013A/en not_active Application Discontinuation
- 2011-01-12 CA CA2786953A patent/CA2786953A1/en not_active Withdrawn
- 2011-01-12 EP EP11700102A patent/EP2523655A2/en not_active Withdrawn
- 2011-01-12 RU RU2012133075/15A patent/RU2012133075A/en unknown
- 2011-01-12 CN CN201180005932XA patent/CN102753150A/en active Pending
- 2011-01-12 US US13/521,377 patent/US20130058999A1/en not_active Abandoned
- 2011-01-12 AU AU2011206629A patent/AU2011206629B2/en not_active Ceased
- 2011-01-12 MX MX2012007806A patent/MX2012007806A/en not_active Application Discontinuation
-
2014
- 2014-05-20 US US14/282,371 patent/US20140255481A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2013517245A (en) | 2013-05-16 |
AU2011206629B2 (en) | 2014-07-17 |
WO2011086093A2 (en) | 2011-07-21 |
CN102753150A (en) | 2012-10-24 |
RU2012133075A (en) | 2014-02-20 |
AU2011206629A1 (en) | 2012-07-12 |
KR20120117013A (en) | 2012-10-23 |
CA2786953A1 (en) | 2011-07-21 |
JP5908847B2 (en) | 2016-04-26 |
MX2012007806A (en) | 2012-08-01 |
EP2523655A2 (en) | 2012-11-21 |
US20140255481A1 (en) | 2014-09-11 |
WO2011086093A3 (en) | 2012-05-24 |
US20130058999A1 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012016853A2 (en) | "pharmaceutical compositions for oral administration of insulin peptides". | |
CY1118813T1 (en) | PHARMACEUTICAL COMPOSITIONS OF TRAMADOL AND COXYL-CYLINDERS | |
IN2012DN06720A (en) | ||
BR112013031268A8 (en) | polypeptides | |
MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
UA113165C2 (en) | APPLICATION OF A COMBINATION OF Baclofen AND ACOMPROSAT FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND A COMPOSITION CONTAINING Baclofen AND ACAMPROSAT | |
IL231536A (en) | Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases | |
EA201690107A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE | |
UA109991C2 (en) | CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION | |
CL2012001836A1 (en) | Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others. | |
MX2019003249A (en) | Diagnosis, prevention and treatment of diseases of the joint. | |
UA115122C2 (en) | Cd3-binding molecules capable of binding to human and non-human cd3 | |
IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
CY1120094T1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING DESPR036 EXPANDH-4 (1-39) -LYS6-NH2 FOR USE IN THE TREATMENT OF A NEUROCOLOGICAL PATIENT | |
MX347734B (en) | S100a4 antibodies and therapeutic uses thereof. | |
ES2446643R1 (en) | Combined pharmaceutical compositions and their use to prepare a drug for the treatment of vertigo, motion sickness and vegetative-vascular dystonia | |
BR112014027981A2 (en) | fumagilol type compounds and methods of production and use thereof | |
TN2012000488A1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
MX344846B (en) | Combination of active loaded granules with additional actives. | |
MX367926B (en) | Pharmaceutical composition for a sustained release of lanreotide. | |
UA109414C2 (en) | Arylated camphenes and pharmaceutical formulation thereof | |
MX2014004953A (en) | Tyrosine based linkers for the releasable connection of peptides. | |
GB201511770D0 (en) | Novel pharmaceutical formulationsand their use in the treatment of periodontal disease | |
UA117154C2 (en) | S1p3 antagonists | |
EE201300004A (en) | A combined pharmaceutical composition for the treatment of diseases or conditions of the cardiovascular system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |